MedPath

Effect of Ursodeoxychoil Acid in Functional Dyspeptic Patients with Small Intestinal Bacterial Overgrowth

Not Applicable
Completed
Conditions
Diseases of the digestive system
Registration Number
KCT0004910
Lead Sponsor
Ajou University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
24
Inclusion Criteria

The Rome IV criteria define FD as one of four symptoms (postprandial fullness, early satiation, epigastric pain, epigastric burning) that occurred at least six months before diagnosis and persisted for the last three months. In addition, examinations involving endoscopy should reveal no structural abnormalities to explain these symptoms.

Exclusion Criteria

Patients with FD were excluded from this study if they had a history of i) gastrointestinal ulcers or inflammatory bowel diseases such as Crohn's disease or ulcerative colitis; ii) gastrectomy or intestinal resection (except appendectomy); or iii) viral liver disease (types A, B, C), cirrhosis, or any cancers, as well as iv) blood tests whose serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) or gamma-glutamyltransferase (GGT) levels were more than three times the normal range or whose serum creatinine levels were more than 1.5 times the normal range; v) chronic renal failure, congestive heart failure, and thyroid disease; vi) persistent alcohol consumption (at least four bottles of soju per week, i.e., at least 240g of alcohol per week); or vii) severe biliary obstruction.

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The questionnaire about dyspepsia measured each patient’s Nepean dyspepsia index-K (NDI-K) and Small intestinal bacterial overgrowth prevalence.
Secondary Outcome Measures
NameTimeMethod
Adverse events
© Copyright 2025. All Rights Reserved by MedPath